Proteomics International Laboratories Ltd (ASX:PIQ)

Market Cap	55.02M
Revenue (ttm)	3.50M
Net Income (ttm)	-7.11M
Shares Out	131.00M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	814,263
Average Volume	241,358
Open	0.4200
Previous Close	0.4100
Day's Range	0.4100 - 0.4300
52-Week Range	0.3550 - 1.1200
Beta	0.14
RSI	52.53
Earnings Date	May 26, 2025

About ASX:PIQ

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PIQ

Financial Performance

In 2024, ASX:PIQ's revenue was 3.28 million, an increase of 2.99% compared to the previous year's 3.18 million. Losses were -6.38 million, 3.23% more than in 2023.